United Therapeutics Co. (UTHR) Shares Bought by Dimensional Fund Advisors LP

Dimensional Fund Advisors LP raised its position in shares of United Therapeutics Co. (NASDAQ:UTHR) by 2.8% in the 4th quarter, HoldingsChannel reports. The institutional investor owned 1,088,982 shares of the biotechnology company’s stock after purchasing an additional 29,427 shares during the quarter. Dimensional Fund Advisors LP’s holdings in United Therapeutics were worth $118,583,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Morgan Stanley raised its holdings in United Therapeutics by 9.5% in the 3rd quarter. Morgan Stanley now owns 243,628 shares of the biotechnology company’s stock valued at $31,154,000 after buying an additional 21,129 shares during the last quarter. Vanguard Group Inc raised its holdings in United Therapeutics by 1.7% in the 3rd quarter. Vanguard Group Inc now owns 3,775,103 shares of the biotechnology company’s stock valued at $482,760,000 after buying an additional 61,361 shares during the last quarter. Retirement Systems of Alabama increased its position in United Therapeutics by 0.4% during the 4th quarter. Retirement Systems of Alabama now owns 56,512 shares of the biotechnology company’s stock valued at $6,154,000 after purchasing an additional 214 shares during the period. Greylin Investment Mangement Inc. acquired a new stake in United Therapeutics during the 4th quarter valued at approximately $13,154,000. Finally, DNB Asset Management AS acquired a new stake in United Therapeutics during the 4th quarter valued at approximately $1,716,000. Institutional investors and hedge funds own 97.65% of the company’s stock.

A number of research firms have weighed in on UTHR. Credit Suisse Group raised shares of United Therapeutics from an “underperform” rating to a “neutral” rating and set a $98.00 target price for the company in a research report on Thursday, May 9th. Wedbush set a $273.00 target price on shares of United Therapeutics and gave the company a “buy” rating in a research report on Wednesday, May 8th. BidaskClub downgraded shares of United Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday, April 19th. ValuEngine downgraded shares of United Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday, April 18th. Finally, Barclays decreased their target price on shares of United Therapeutics from $100.00 to $95.00 and set an “underweight” rating for the company in a research report on Friday, March 1st. Two equities research analysts have rated the stock with a sell rating, seven have given a hold rating and three have issued a buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus target price of $132.89.



In other news, Director Christopher Patusky sold 3,370 shares of the firm’s stock in a transaction that occurred on Thursday, March 7th. The shares were sold at an average price of $110.75, for a total transaction of $373,227.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 8.20% of the company’s stock.

NASDAQ:UTHR opened at $90.74 on Tuesday. The company has a market cap of $3.98 billion, a price-to-earnings ratio of 6.78 and a beta of 1.01. The company has a debt-to-equity ratio of 0.45, a current ratio of 7.19 and a quick ratio of 6.84. United Therapeutics Co. has a fifty-two week low of $90.04 and a fifty-two week high of $130.00.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings data on Wednesday, May 1st. The biotechnology company reported ($11.32) EPS for the quarter, missing the consensus estimate of $2.64 by ($13.96). The company had revenue of $362.70 million for the quarter, compared to analyst estimates of $335.72 million. United Therapeutics had a negative return on equity of 5.78% and a negative net margin of 9.36%. The business’s quarterly revenue was down 6.8% compared to the same quarter last year. During the same period last year, the business earned $3.76 EPS. On average, sell-side analysts expect that United Therapeutics Co. will post -5.03 EPS for the current year.

COPYRIGHT VIOLATION WARNING: This article was originally published by Dakota Financial News and is the sole property of of Dakota Financial News. If you are accessing this article on another site, it was illegally stolen and republished in violation of US & international trademark & copyright legislation. The original version of this article can be viewed at https://dakotafinancialnews.com/2019/05/14/united-therapeutics-co-uthr-shares-bought-by-dimensional-fund-advisors-lp.html.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases primarily in the United States and Europe. The company's commercial therapies include Remodulin, an infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension (PAH) patients; Tyvaso, an inhaled formulation of treprostinil to enhace the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients; and Unituxin, a monoclonal antibody for treating neuroblastoma.

Featured Article: Portfolio Manager

Want to see what other hedge funds are holding UTHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for United Therapeutics Co. (NASDAQ:UTHR).

Institutional Ownership by Quarter for United Therapeutics (NASDAQ:UTHR)

Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.